Isis Pharmaceuticals Income Statement
View: Annual | Quarterly
| Dec 08 | Dec 07 | Dec 06 | |
|---|---|---|---|
| Revenue | 107.2 | 69.6 | 24.5 |
| Cost of Goods Sold | 0.0 | -- | -- |
| Gross Profit | -- | -- | -- |
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| SG&A Expense | 13.8 | 15.9 | 12.6 |
| Depreciation & Amortization | 6.8 | 5.2 | 5.5 |
| Operating Income | -- | -- | -- |
| Operating Margin | -- | -- | -- |
| Nonoperating Income | 15.1 | 35.5 | 8.2 |
| Nonoperating Expenses | (5.6) | -- | -- |
| Income Before Taxes | -- | -- | -- |
| Income Taxes | -- | -- | -- |
| Net Income After Taxes | 0.0 | 0.0 | 0.0 |
| Continuing Operations | (3.6) | (136.3) | (68.9) |
| Discontinued Operations | (8.4) | -- | -- |
| Total Operations | (12.0) | (136.3) | (68.9) |
| Total Net Income | (12.0) | (136.3) | (68.9) |
| Net Profit Margin | -- | -- | -- |
| Diluted EPS from Total Net Income ($) | (0.13) | (1.63) | (0.62) |
| Dividends per Share | 0.00 | 0.00 | 0.00 |
© 2009 Morningstar, Inc. Financial Data provided by
